Subscribe to our Newsletter Abonnez-vous à notre newsletter
By subscribing to our Newsletter you will receive Sernova’s press releases and news as they develop by email. We do not send direct mail, customized online advertising, and we do not share your personal information. We respect your privacy. En vous abonnant à notre newsletter, vous recevrez par e-mail les communiqués de presse et les actualités de Sernova au fur et à mesure de leur développement. Nous n'envoyons pas de publipostage, de publicité en ligne personnalisée et nous ne partageons pas vos informations personnelles. Nous respectons votre vie privée.
Please read our Pour plus d’informations, veuillez lire notre Privacy policypolitique de confidentialité.
Press Release Communiqué de presse - April 06, 2021 6 April, 2021
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
April 6, 2021 9:00 am ET
LONDON, ONTARIO – April 6, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a
leading
clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal
investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes
clinical trial will present data and observations from the ongoing study in a poster presentation at the
upcoming
American Diabetes Association’s (ADA) 81st Scientific Sessions to be held June 25 - 29, 2021.
The abstract will also be published online at the journal Diabetes® website and the presentation will be
available to conference attendees on Friday, June 25, 2021.
Dr. Witkowski, Director, Pancreatic and Islet Transplant Program at the University of Chicago, is also
scheduled
to deliver a lecture titled “Islet Transplantation – Benefits and Shortcomings”, as part of the Clinical and
Regulatory Hurdles Facing Islet Transplantation session on Monday, June 28, 2021, at 8:00 am ET.
Note: all information contained in the submitted abstract should be considered preliminary and subject to
change until the study data and observations are fully presented at the ADA 81st Scientific Sessions and is
subject to embargo until June 25, 2021, at 11:30 am ET.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The
device
upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for
the
transplantation and function of therapeutic cells, which then release proteins and hormones as required to
treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and
efficacy in small and large animal models of diabetes and has been proven to provide a biologically
compatible
environment for insulin-producing cells in humans.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and
immune
protected therapeutic cells ( i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins
or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT THE ADA’s SCIENTIFIC SESSIONS
The American Diabetes Association’s (ADA) 81st Scientific Sessions, the world’s largest scientific meeting
focused on diabetes research, prevention, and care, will be held virtually June 25-29, 2021. Leading
physicians, scientists, and health care professionals from around the world will unveil cutting-edge research,
treatment recommendations and advances toward a cure for diabetes. Though the conference will be
remote
this year, attendees will receive exclusive access to nearly 2,000 original research presentations and take
part
in provocative and engaging exchanges with leading diabetes experts. Learn more and register at
scientificsessions.diabetes.org and join the Scientific Sessions conversation on social media using
#ADA2021.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may
constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible,
but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or
"should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited
to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at
all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to
execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should
consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks
and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information,
future
events or otherwise.
Press Release Communiqué de presse - March 15, 2021 15 March, 2021
Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases
Sernova is the first and only regenerative medicine therapeutics platform company to demonstrate a well-
vascularized subcutaneous islet transplant technology achieving persistent islet graft function in diabetic
patients
Sernova CEO hosting an investor conference call on March 18, 2021 at 11:00 am (EDT)
March 15, 2021 9:00 a.m. EDT
LONDON, ONTARIO – March 15, 2021 – Sernova Corp. (TSX-V:SVA) (FSE/XETRA:PSH) (OTCQB:SEOVF), a
clinical-stage regenerative medicine company, today provides a Corporate Update and highlights recent key
achievements in its pipeline, including its diabetes clinical program as well as other leading development
programs.
“I am pleased that our clinical study based on our unique technology platform continues to contribute
significant advancements to the field of regenerative medicine therapeutics. This is demonstrated by ongoing
positive patient outcomes in safety, tolerability, and efficacy measures as we actively approach completion of
full study enrolment. These advancements are occurring despite ongoing global uncertainty related to the
COVID-19 pandemic. In this restrictive environment, Sernova also achieved significant advancements in our
other therapeutic programs and in the development of technologies that we believe are building significant
shareholder value and justified optimism for patients suffering from chronic diseases. As validation of our
strategic approach, we are pleased with the recently completed institutional led bought deal financing of $23M.
We are aggressively moving forward with all of our programs,” said Dr. Philip Toleikis, President and CEO of
Sernova.
DIABETES : SERNOVA’S LEAD CLINICAL INDICATION
Sernova’s principal investigator in its US Phase I/II diabetes clinical trial, Dr. Piotr Witkowski, presented an
update at the recent 2021 21st Winter Symposium of the American Society of Transplant Surgeons based on
data from its current clinical trial: A Safety, Tolerability and Efficacy -Study of Sernova's Cell Pouch for Clinical
Islet Transplantation.
Five of the 7 planned patients have been enrolled, implanted with the Cell Pouch, and are advancing through
the transplantation phases of the study.
The following key findings to date have been noted in our trial patients:
• The Primary Safety Endpoint of the study continues to be met:
o the Cell Pouch, following implantation under the skin, shows consistent incorporation with vascularized
tissue in multiple patients providing a suitable environment for the survival and function of insulin producing
cells; and
o the implanted Cell Pouch and therapeutic cells continue to demonstrate a positive safety profile with no
serious adverse events related to the Cell Pouch.
• The Secondary Efficacy measures continue to show clinical benefit in the most advanced treated patients
including:
o absence of life-threatening hypoglycemic episodes;
o enduring presence of insulin produced by the Cell Pouch transplanted cells (measured by the biomarker C-
peptide) in the bloodstream;
o reduction or elimination in the daily amount of insulin injected; and
o a reduction in HbA1c, a measure of long-term blood sugar control, which can lead to reduced diabetic
complications.
Pre-screening of the final two patients is actively underway to complete study enrollment.
HEMOPHILIA A
Sernova as a member of the Horizon 2020 HemAcure Consortium (HemAcure Consortium) presented results of
the Consortium’s research at the American Society of Gene and Cell Therapy. Importantly, the following
highlights were presented:
• hemophilia A patients unable to express the required clotting factor VIII (FVIII) blood cells were isolated;
• the human FVIII gene responsible for the production of the missing required clotting factor was
successfully inserted to achieve a therapeutic effect;
• the safety of these newly corrected cells and their ability to produce sufficient human clotting factor both
in laboratory and in an initial preclinical animal model was confirmed.
o human FVIII blood levels reached up to 10%, which is considered sufficient to enable patients to regain
their clotting ability;
o these corrected therapeutic cells in the Cell Pouch were successfully assessed in a preclinical model of
hemophilia A showing long-term survival of cells;
o human FVIII was also detected in the bloodstream long-term (measured up to four months, the length of
the study, following treatment); and
• data further confirmed functional clotting improvement in the blood at the four months time point where
human FVIII corrected cells transplanted into the hemophilia A preclinical model restored the animals clotting
activity to a therapeutic level within the Cell Pouch.
“These results demonstrate the success in developing a novel approach for the treatment of hemophilia A.
These results continue to showcase Sernova’s Cell Pouch platform technologies for the treatment of multiple
indications including rare diseases where a gene can be inserted into cells to produce any protein or factor
required to treat disease,” added Toleikis. “We look forward to completing work to bring this and other novel
therapies to human clinical testing as soon as practicable.”
HYPOTHYROID DISEASE
Sernova is developing a treatment for hypothyroid disease following complete or partial removal of the thyroid
gland (thyroidectomy). To advance this platform technology, in collaboration with Dr. Sam Wiseman and in part
funded by a Transplant Venture Grant awarded by the Transplant Research Foundation (TRF) of British
Columbia, we are assessing healthy human thyroid tissue in preparation of a clinical program.
This new treatment approach allows patients to preserve their thyroid function following a thyroidectomy by
transplanting healthy thyroid cells into Sernova’s Cell Pouch. Currently completed pre-clinical work is setting
the stage for a regulatory submission for this second clinical program.
PLATFORM EXPANDING TECHNOLOGIES AND CORPORATE COLLABORATIONS
Sernova is acquiring and developing state of the art technologies. These involve both unique cell encapsulating
technologies and gene editing technologies to reduce or eliminate the need for immunosuppression
medications targeted to our specific cell therapy clinical applications within the Cell Pouch platform.
• Sernova has acquired all the patented technology and knowhow for a cellular local immune protection
technology (Conformal Coating Technology)
o an exclusive worldwide license agreement with the University of Miami was signed, broadening this
technology scope.
o Sernova intends on bringing the Cell Pouch platform technologies, which includes conformally coated
therapeutic cell technology, to the clinic first for our diabetes donor and stem cell programs with the goal to
improve current cell therapy treatment options.
• Sernova also entered into a collaboration agreement with AgeX Therapeutics to utilize their UniverCyte™
technology. The objective is to generate transplantable genetically engineered stem cells that are immune
protected to treat diseases for use in Sernova’s Cell Pouch.
Sernova is in active collaborations with leading global pharmaceutical companies for multiple cell therapy
clinical applications in combination with Sernova’s cell therapy therapeutic platform and technologies. The goal
of these collaborations is to initiate co-development and/or licensing agreements, as well as the potential
ability to market and distribute our regenerative medicine therapeutics worldwide.
Dr. Toleikis will participate in the first of a series of conference calls for shareholders to provide corporate
updates and answer questions at 11:00 am (EDT) on March 18, 2021. A presentation will be made available on
Sernova’s website before the call. All questions to Dr. Toleikis can be submitted to info@sernova.com prior to
the call. To participate in this live conference call, please visit:
Meeting link:
https://sernovacorp.my.webex.com/sernovacorp.my/j.php?MTID=md016888548d385cd4fea3878b73a9b5d
Meeting number: 182 490 4245
Password: SVAMarch2021 (78262724 from phones and video systems)
Join by phone
+1-416-915-6528 CANADA TOLL
+1-415-655-0001 US TOLL
Access code: 182 490 4245
(Global call-in numbers available upon request)
Following the conference call a recording will be available at www.sernova.com
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information, please contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Press Release Communiqué de presse - March 01, 2021 1 March, 2021
SERNOVA ANNOUNCES CLOSING OF C$23 MILLION BOUGHT DEAL FINANCING INCLUDING FULL EXERCISE OF OVER-ALLOTMENT OPTION
LONDON, ONTARIO – March 1, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB:
SEOVF) (Frankfurt/Xetra: PSH), a leading clinical-stage regenerative medicine therapeutics company, is
pleased to announce that it has closed its previously announced bought deal financing of 16,700,000 units of
the Company (the “Units”) at a price of C$1.20 per Unit (the “Issue Price”), and the exercise in full of the
Over-Allotment Option of 2,505,000 Units at the Issue Price, for aggregate gross proceeds to the Company
of approximately C$23,046,000 (the “Offering”).
Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share
purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share
(as “Warrant Share”) at an exercise price of C$1.70 (the “Exercise Price”) until March 1, 2023. The expiry
date of the Warrants may be accelerated by the Company if the daily volume weighted average trading price
of the Common Shares on the TSX Venture Exchange (the “Exchange”) is greater than C$3.05 for the
preceding ten (10) consecutive trading days, at which time the Company may accelerate the expiry date of
the Warrants by providing notice to the holders of Warrants or issuing a news release announcing such
acceleration, whereupon the Warrants will expire not less than 30 days after the date of such notice or news
release.
The Offering was conducted on a “bought deal” basis, led by Canaccord Genuity Corp. and Leede Jones
Gable Inc. as co-lead underwriters (together, the “Underwriters). As consideration for their services in
connection with the Offering, the Company paid to the Underwriters: (i) a cash commission of $1,452,981;
(ii) a corporate finance fee of 384,100 Units; and (iii) 1,210,818 compensation options (the “Compensation
Options”), where each Compensation Option entitles the holder thereof to purchase one Unit (a
“Compensation Unit”) at the Issue Price until March 1, 2023. Each Compensation Unit is comprised of one
Share and one Warrant exercisable into a Warrant Share at the Exercise Price.
The net proceeds of the Offering will be used to advance the Company’s clinical development programs, including its US Phase I/II Cell Pouch clinical trial in insulin-dependent diabetes, expand the Company’s
research and development programs, including its local immune protection technologies for the Cell Pouch,
as well as for working capital and general corporate purposes.
The Offering was completed (i) by way of a short form prospectus filed in each of the provinces of Canada,
other than Quebec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, (ii) on a
private placement basis in the United States pursuant to exemptions from the registration requirements of
the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and applicable U.S. state
securities laws, and (iii) outside Canada and the United States on a basis which does not require the
qualification or registration of any of the Company’s securities under domestic or foreign securities laws.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to,
or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the
U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a
solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such
offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be
made by means of a prospectus containing detailed information about the company and management, as
well as financial statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
T: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian
securities legislation. These statements relate to future events or future performance. The use of any of the
words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and
statements relating to matters that are not historical facts are intended to identify forward-looking
information and are based on Sernova’s current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release includes information with respect to the
intended use of proceeds by the Company. Forward-looking information is based on reasonable
assumptions that have been made by Sernova at the date of the information and is subject to known and
unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially
from those anticipated in the forward-looking information. Examples of such risk factors include: credit;
market (including equity, foreign exchange and interest rate); liquidity; operational (including technology and
infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the
general business and economic conditions in the regions in which the Company operates; the ability of the
Company to execute on key priorities, including the successful development of its product candidates, and
strategic plans and to attract, develop and retain key executives; the ability to implement business strategies
and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's
information technology; the failure of third parties to comply with their obligations to the Company or its
affiliates; the impact of new and changes to, or application of, current laws and regulations governing the
Company’s business; dependence on key suppliers; granting of permits and licenses; increased competition;
changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and
competition for funding; the availability of funds and resources to pursue operations; critical accounting
estimates and changes to accounting standards, policies, and methods used by the Company; the
occurrence of natural and unnatural catastrophic events and claims resulting from such events; risks related
to COVID-19 including various recommendations, orders and measures of governmental authorities to try to
limit the pandemic, including travel restrictions, border closures, nonessential business closures,
quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic
activity, financing, supply chains and sales channels, and a deterioration of general economic conditions
including a possible national or global recession; as well as those risk factors disclosed under the heading
“Risk Factors” in the Company’s Annual Information Form (dated February 8, 2021) for the year ended
October 31, 2020, which has been filed on SEDAR and is available under the Company’s profile at
www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these
forward-looking statements. The forward-looking information contained in this press release is made as of
the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether
as a result of new information, future events or otherwise, except as required by applicable securities laws.
The foregoing statements expressly qualify any forward-looking information contained herein.
Press Release Communiqué de presse - February 25, 2021 25 February, 2021
Sernova Corp. Selected for the TSX Venture Stock Exchange’s 2021 Venture 50 List of Top Performing Listed Companies
February 25, 2021 9:00 a.m. EST
LONDON, ONTARIO - February 25, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF)
(Frankfurt/Xetra:PSH), a clinical-stage company and leader in regenerative medicine therapeutics is pleased
to announce that the TSX Venture Stock Exchange (TSX Venture) has recognized Sernova as a 2021 Venture
50 company, showcasing the top 50 performing listed companies.
“We are honoured to be chosen for the 2021 Venture 50 list and to be included amongst this distinguished
group of industry leaders. We share this honour with our institutional and retail investors who are supporting
our continued success and growth,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “This
recognition is another validation of Sernova’s ongoing therapeutic advancements and builds upon what will
be another very strong year as we continue to grow the company and build further shareholder value.”
The Venture 50 are the top ten companies listed on TSX Venture Exchange in each of five major industry
sectors – mining, energy & energy services, clean technology & life sciences, diversified industries and
technology – based on a ranking formula with equal weighting given to market cap growth, trading volume
amount and share price appreciation. All data was as of December 31, 2020.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch system including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The
device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the
transplantation and function of therapeutic cells which then release proteins and hormones as required to
treat disease. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and
efficacy in small and large animal models of diabetes and has been proven to provide a biologically
compatible environment for insulin-producing cells in humans. In early assessments of its ongoing Phase I/II
clinical trial, Sernova has shown presence of blood levels of c-peptide both during glucose tolerance tests as
well as under fasting conditions. Clinical testing is ongoing at the University of Chicago.
ABOUT SERNOVA CORP
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and
immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived
cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are
not historical facts and are generally, but not always, identified by the words “expects”, “plans”,
“anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that
events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the
expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance, and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions
of Sernova’s management on the date such statements were made, which include our beliefs about the
conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information, future events or otherwise.
Press Release Communiqué de presse - February 24, 2021 24 February, 2021
Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
LONDON, ONTARIO – February 24, 2021 – Sernova Corp. ("Sernova" or the "Company") (TSX-V: SVA)
(OTCQB: SEOVF) (Frankfurt/Xetra:PSH), a leading clinical-stage regenerative medicine therapeutics company,
is pleased to announce it has received a receipt for its final short form prospectus dated February 24, 2021 (the
"Final Prospectus") in connection with its previously announced bought deal offering of 16,700,000 units of the
Company (the "Units") at a price of C$1.20 per Unit for gross proceeds of approximately C$20,040,000 (the
"Offering"). Canaccord Genuity Corp. and Leede Jones Gable Inc. are the co-lead underwriters (together, the
"Underwriters") of the Offering.
The Company expects to close the Offering on or around March 1, 2021.
The Company has granted the Underwriters an option, exercisable in part or in whole at the Underwriter's sole
discretion, at any time until 30 days following closing, to purchase up to that number of additional Units equal
to 15% of the aggregate number of Units sold in the Offering.
The Final Prospectus was filed with the securities regulatory authorities in all provinces of Canada, except
Quebec, and is available under the Company's SEDAR profile at www.sedar.com.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S.
registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation
for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation
or sale would be unlawful. Any public offering of securities in the United States must be made by means of a
prospectus containing detailed information about the company and management, as well as financial
statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e., human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains 'forward-looking information' within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future performance. The use of any of the words
"could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to identify forward-looking information and are
based on Sernova's current belief or assumptions as to the outcome and timing of such future events. Forward
looking information in this press release includes information with respect to the Offering, including the timing
and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the
intended use of proceeds by the Company and the exercise of the Over-allotment Option by the Underwriters.
Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date
of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause
actual results or events to differ materially from those anticipated in the forward-looking information.
Examples of such risk factors include: the inability of the Company to close the Offering or to obtain all
necessary Exchange and regulatory approvals; credit; market (including equity, foreign exchange and interest
rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic;
regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the
regions in which the Company operates; the ability of the Company to execute on key priorities, including the
successful development of its product candidates, and strategic plans and to attract, develop and retain key
executives; the ability to implement business strategies and pursue business opportunities; disruptions in or
attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to
comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application
of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of
permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and
market volatility due to market illiquidity and competition for funding; the availability of funds and resources to
pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods
used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from
such events; risks related to COVID-19 including various recommendations, orders and measures of
governmental authorities to try to limit the pandemic, including travel restrictions, border closures,
nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions
to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general
economic conditions including a possible national or global recession; as well as those risk factors disclosed
under the heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the
years ended October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s
profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on
these forward-looking statements. The forward-looking information contained in this press release is made as
of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether
as a result of new information, future events or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking information contained herein.
Press Release Communiqué de presse - February 18, 2021 18 February, 2021
Sernova Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System™ Clinical Trial and Recommendation for Protocol Continuation
Ongoing Safety of Sernova's Clinical Trial Confirmed
February 18, 2021 9:00 a.m. EST
LONDON, ONTARIO – February 18, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-
stage company and leader in regenerative medicine therapeutics, is pleased to announce that the clinical trial
independent Data Safety Monitoring Board ("DSMB") has completed the second planned annual review of the
ongoing Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation Phase
I/II clinical trial in patients with severe hypoglycemia unawareness and inability to produce their own insulin.
The DSMB recommended that the Phase I/II clinical study should continue according to the study protocol and
any related amendments. In their assessment, the DSMB did not raise any concerns regarding patient safety.
"We are pleased with the second annual independent DSMB review of our Phase I/II clinical trial," said Dr.
Philip Toleikis, President & CEO Sernova Corp. "We thank the DSMB for its diligence, guidance and support as
Sernova continues progressing the clinical trial."
The DSMB is an independent group of clinical research experts who review the accumulated data to permit a
thorough evaluation of patient safety and to ensure the integrity of the study's data and progress towards
completion.
ABOUT SERNOVA'S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess
the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects
with hypoglycemia unawareness and an inability to produce their own insulin. The secondary objective is to
assess efficacy through a series of defined measures. Eligible subjects are implanted with Cell Pouches.
Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on
immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional
safety and efficacy measures for approximately six months. At this point, a decision will be made with regards
to the transplant of a second islet dose with subsequent safety and efficacy follow-up. Following this period,
eligible patients may be administered a single dose of islets through the portal vein. Patients will be then further
followed for one year to assess longer-term safety and efficacy. This study is supported in part by funding from
JDRF, the leading global organization funding type 1 diabetes (T1D) research.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA'S CELL POUCH SYSTEM
The Cell Pouch system including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long- term survival and function of therapeutic cells. The device
is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and
function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell
Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large
animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-
producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown
presence of blood levels of c-peptide both during glucose tolerance tests as well as under fasting conditions.
Clinical testing is ongoing at the University of Chicago.
ABOUT SERNOVA CORP
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions
"will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Press Release Communiqué de presse - February 04, 2021 4 February, 2021
Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany
February 4, 2021 9:00 a.m. EST
LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading
clinical-stage regenerative medicine therapeutics company, is pleased to announce the start of trading of
Sernova shares on Xetra, the electronic trading system of Deutsche Börse AG in Germany (German
Securities Identification Number (WKN): A0LBCR, International Securities Identification Number (ISIN):
CA81732W1041, German Ticker-Symbol: PSH).
Xetra is an electronic trading platform operated by the Frankfurt Stock Exchange. It offers trading in stocks,
funds, bonds, warrants, and commodities contracts. Launched in 1997, the majority of stock market
transactions in Germany are through the Xetra trading venue: approximately 90 percent of all trading in
shares across all German exchanges is now conducted through Xetra making it the largest of Germany’s
stock exchanges. Over 200 trading participants from 16 European countries, United Arab Emirates and
Hong Kong are connected via Xetra servers.
Xetra is the first and primary choice for institutional investors with its significantly higher liquidity and
narrower price spreads. Given the high turnover (liquidity) on the Xetra trading venue, orders for securities
are executed swiftly and at prices in line with the market. Moreover, this principle is supported by
Designated Sponsors who post binding purchase and selling prices (quotes) continuously and thus ensure
additional liquidity and fair prices, making it the first choice for institutional investors. mwb
Wertpapierhandelsbank AG will act as Designated Sponsor (active market maker) to handle the trading of
Sernova’s shares on Xetra with immediate effect and therefore contribute to increased trading liquidity.
mwb fairtrade Wertpapierhandelsbank AG (www.mwbfairtrade.com) is a securities service provider licensed
by the German Federal Financial Supervisory Authority (BaFin) with branches near Munich, Hamburg,
Hanover, Frankfurt as well as Berlin. Founded in 1993 and active in two business divisions: Securities
Trading and Corporates & Markets, mwb manages approximately 40,000 order books for German and
international securities as well as 89 Designated Sponsors mandates making mwb one of the largest order
book managers in Germany.
“mwb has developed in-depth knowledge on enabling Xetra trading for overseas companies. We are happy
to support Sernova with the rollout of their exciting equity story and look forward to enhance Euro-based
trading possibilities for their institutional and retail investor base in Europe,” said Sascha Guenon, Head of
Designated Sponsoring and Corporate Broking at mwb.
“We are experiencing a significant increase of interest from institutional investors in Europe, especially in
German-speaking countries, and want to provide them with a more efficient way to trade our shares,"
commented Dr. Philip Toleikis, President and CEO of Sernova. "This is an important step to increase the
percentage of long-term oriented institutional investors within our group of shareholders who understand
the potential of our innovative platform technologies in the regenerative medicine field as well as the
valuation gap with our competitors. mwb has a strong network of biotech investors and we are looking
forward to presenting the potential of Sernova’s regenerative medicine platform to them.”
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are
not historical facts and are generally, but not always, identified by the words “expects”, “plans”,
“anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that
events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the
expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance, and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions
of Sernova’s management on the date such statements were made, which include our beliefs about the
conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information, future events or otherwise.
Press Release Communiqué de presse - February 04, 2021 4 February, 2021
Sernova Upsizes Previously Announced Bought Deal Public Offering to C$20 Million
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB:
SEOVF)(FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to
announce that it has entered into an amendment (the “Amendment”) to its previously announced agreement
with Canaccord Genuity Corp. and Leede Jones Gable Inc., as co-lead underwriters (together, the
“Underwriters”), pursuant to which the Underwriters have agreed to increase the size of the previously
announced bought deal financing. Pursuant to the Amendment, the Underwriters have agreed to purchase, on a
bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 16,700,000 units of the
Company (the “Units”) at a price of C$1.20 per Unit for gross proceeds to the Company of approximately
C$20,040,000 (the “Offering”).
The Company has granted the Underwriters an option (the “Over-allotment Option”), exercisable in part or in
whole at the Underwriters’ discretion, at any time until thirty (30) days following the Closing Date, to purchase
up to the number of additional Units equal to 15% of the aggregate number of Units sold in the Offering to
cover over-allotments, if any.
All other terms of the Offering remain consistent with the Company’s previous announcement on February 3,
2021.
The net proceeds of the Offering will be used to advance the Company’s clinical development program,
including its US Phase I/II Cell Pouch clinical trial, expand Sernova’s research and development programs,
including our local immune protection technologies for the Cell Pouch, as well as for working capital and
general corporate purposes.
The Offering will be completed (i) by way of a short form prospectus to be filed in those provinces of Canada
other than Quebec as the Underwriters and the Company may designate pursuant to National Instrument 44-
101 – Short Form Prospectus Distributions, (ii) on a private placement basis in the United States pursuant to
exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the
“U.S. Securities Act”), and applicable U.S. state securities laws, and (iii) outside Canada and the United States
on a basis which does not require the qualification or registration of any of the Company’s securities under
domestic or foreign securities laws.
The Offering is expected to close on February 24, 2021 and is subject to certain customary conditions including
the approval of the TSX Venture Exchange and applicable securities regulatory authorities.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S.
registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation
for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation
or sale would be unlawful. Any public offering of securities in the United States must be made by means of a
prospectus containing detailed information about the company and management, as well as financial
statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
T: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future performance. The use of any of the words
“could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements
relating to matters that are not historical facts are intended to identify forward-looking information and are
based on Sernova’s current belief or assumptions as to the outcome and timing of such future events. Forward
looking information in this press release includes information with respect to the Offering, including the timing
and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the
intended use of proceeds by the Company and the exercise of the Over-allotment Option by the Underwriters.
Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date
of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause
actual results or events to differ materially from those anticipated in the forward-looking information.
Examples of such risk factors include: the inability of the Company to close the Offering or to obtain all
necessary Exchange and regulatory approvals; credit; market (including equity, foreign exchange and interest
rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic;
regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions
in which the Company operates; the ability of the Company to execute on key priorities, including the
successful development of its product candidates, and strategic plans and to attract, develop and retain key
executives; the ability to implement business strategies and pursue business opportunities; disruptions in or
attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to
comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application
of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of
permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and
market volatility due to market illiquidity and competition for funding; the availability of funds and resources to
pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods
used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from
such events; risks related to COVID-19 including various recommendations, orders and measures of
governmental authorities to try to limit the pandemic, including travel restrictions, border closures,
nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions
to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general
economic conditions including a possible national or global recession; as well as those risk factors disclosed
under the heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the
years ended October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s
profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on
these forward-looking statements. The forward-looking information contained in this press release is made as
of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether
as a result of new information, future events or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking information contained herein.
Privacy PolicyPolitique de confidentialité
Updated July 6, 2018
Please read this Policy carefully along with our Legal Notice that describes our Terms of Use for the Website.
By accessing www.sernova.com (the “Website”) you hereby agree with the practices described in this Privacy Policy (the “Policy”)
This Policy applies to all information gathered through the Website and/or any related marketing technique or events.
Information Collection
The information collected is limited to the information that you decide to share with us through the News Dispatch Service, when participating at event or activities or in the general course of business by expressing an interest in obtaining information about Sernova Corp. and our products, such as name, email, phone number, and similar contact information. This information is stored through MailChimp (please refer to MailChimp Privacy Policy at https://mailchimp.com/legal/privacy/).
Information Sharing
Sernova Corp. is the sole owner of any information collected on the Website. We do not sell, share or rent this information to others.
Traffic and Automatic Information Collection
Sernova Corp. maintains log files of the traffic on www.sernova.com. This information is not linked to any personal information that you have provided us. Logs are used to manage traffic, identify content accessed, and IT requirements. Information logged and automatically collected includes without being limited to IP addresses and browser types. This information does not reveal your specific identity.
Cookies
Cookies can be used to provide you with a more personalized experience. The Website may use cookies to make that experience more companionable when you return to the Website. You have the option at all time to decline the use of cookies. If you choose to do so, you may not be able to fully use all features of the Website. You can also delete cookie files at all time from your computer. Those cookies may include first-party cookies (such as the Google Analytics cookies).
Updates
This Policy is a living document and may be amended or updated from time to time without further notice. We encourage you to review the Policy periodically.
Contact
If you have any questions or comments about our policy, you can email us at info@sernova.com or by phone at 1(877) 299-4603 or by mail at
Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8
Mis à jour le 6 juillet 2018
Veuillez lire attentivement cette politique ainsi que notre avis juridique qui décrit nos conditions d'utilisation du site Web.
En accédant à www.sernova.com (le «site Web»), vous acceptez les pratiques décrites dans la présente politique de confidentialité (la «politique»).
Cette politique s'applique à toutes les informations collectées via le site Web et / ou toute technique ou événement marketing associé.
Collecte d'informations
Les informations collectées se limitent aux informations que vous décidez de partager avec nous par le biais du service d’expédition de nouvelles, lorsque vous participez à un événement ou à des activités ou que vous vous intéressez à obtenir des informations sur Sernova Corp. comme nom, email, numéro de téléphone et informations de contact similaires. Ces informations sont stockées via MailChimp (veuillez vous reporter aux règles de confidentialité de MailChimp sur https://mailchimp.com/legal/privacy/).
Partage d'information
Sernova Corp. est l'unique propriétaire de toute information collectée sur le site Web. Nous ne vendons pas, ne partageons pas ou ne louons pas ces informations à des tiers.
Collecte d'informations routières et automatiques
Sernova Corp. gère les fichiers journaux du trafic sur www.sernova.com. Ces informations ne sont liées à aucune information personnelle que vous nous avez fournie. Les journaux sont utilisés pour gérer le trafic, identifier le contenu accédé et les besoins informatiques. Les informations consignées et collectées automatiquement ne sont pas limitées aux adresses IP et aux types de navigateur. Cette information ne révèle pas votre identité spécifique.
Cookies
Les cookies peuvent être utilisés pour vous offrir une expérience plus personnalisée. Le site Web peut utiliser des cookies pour rendre cette expérience plus conviviale lorsque vous revenez sur le site Web. Vous avez la possibilité à tout moment de refuser l'utilisation de cookies. Si vous choisissez de le faire, vous ne pourrez peut-être pas utiliser toutes les fonctionnalités du site Web. Vous pouvez également supprimer des fichiers de cookies à tout moment depuis votre ordinateur. Ces cookies peuvent inclure des cookies de première partie (tels que les cookies de Google Analytics).
Mises à jour
Cette politique est un document évolutif et peut être modifié ou mis à jour de temps à autre sans préavis. Nous vous encourageons à consulter la politique périodiquement.
Contact
Si vous avez des questions ou des commentaires sur notre politique, vous pouvez nous envoyer un courriel à info@sernova.com ou par téléphone au 1 (877) 299-4603 ou par courrier à
Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8